Mankind Pharma is majority-owned by promoters at 76.5% stake, while the public owns the remaining 23.5%. Among the public shareholders, mutual funds own 3.9%, while foreign investors have another 3.9%. Shares of the company delivered 30% returns over a 12-month period, outperforming the Nifty Index, which has given nearly 13% returns during this time.
| Subscribe To Our Free Newsletter |
